Vol 62, No 6 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia

Dilek Yesilbursa, Akin Serdar, Yelda Saltan, Zehra Serdar, Yasemin Heper, Sevil Guclu, Jale Cordan
Kardiol Pol 2005;62(6):530-530.
Vol 62, No 6 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Lipid lowering therapy with statins is beneficial because of improvement in lipoprotein concentrations and additional pleiotropic effects. However, less is known about the pleotropic effect of fibrates.
Aim: To investigate the effects of fenofibrate therapy on inflammatory markers and serum paraoxonase activity in patients with combined hyperlipidemia in addition to their lipid lowering effects.
Methods: Fifty patients (18 women, 32 men, mean age 50±8.7 years) with a history of combined hyperlipidemia and coronary artery disease were enrolled into the study. Serum lipids, inflammatory markers (high sensitivity C-reactive protein (hs-CRP) and fibrinogen levels) and paraoxonase levels were determined before and after two months of 250 mg per day of fenofibrate treatment.
Results: Fenofibrate decreased plasma fibrinogen level by 41% (from 3.9±0.9 mg/dl to 2.3±0.48 mg/dl, p

Abstract

Background: Lipid lowering therapy with statins is beneficial because of improvement in lipoprotein concentrations and additional pleiotropic effects. However, less is known about the pleotropic effect of fibrates.
Aim: To investigate the effects of fenofibrate therapy on inflammatory markers and serum paraoxonase activity in patients with combined hyperlipidemia in addition to their lipid lowering effects.
Methods: Fifty patients (18 women, 32 men, mean age 50±8.7 years) with a history of combined hyperlipidemia and coronary artery disease were enrolled into the study. Serum lipids, inflammatory markers (high sensitivity C-reactive protein (hs-CRP) and fibrinogen levels) and paraoxonase levels were determined before and after two months of 250 mg per day of fenofibrate treatment.
Results: Fenofibrate decreased plasma fibrinogen level by 41% (from 3.9±0.9 mg/dl to 2.3±0.48 mg/dl, p
Get Citation

Keywords

combined hyperlipidemia - fenofibrate- inflammatory markers - paraoxonase

About this article
Title

The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 62, No 6 (2005)

Pages

530-530

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2005;62(6):530-530.

Keywords

combined hyperlipidemia - fenofibrate- inflammatory markers - paraoxonase

Authors

Dilek Yesilbursa
Akin Serdar
Yelda Saltan
Zehra Serdar
Yasemin Heper
Sevil Guclu
Jale Cordan

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl